Oral Cancer Awareness in Egypt

Sponsor
Ayat Gamal-AbdelNaser (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05604105
Collaborator
Ahram Canadian University (Other)
5,000
7

Study Details

Study Description

Brief Summary

Oral cancer is a fatal disease with high prevalence and poor survival rate. Most oral cancer cases can be detected by the patients themselves. So, when a patient is aware of oral caner, the patient would realize its signs and symptom and seek early medical care; therefore, improving the prognosis.

To our knowledge, the level of awareness of oral cancer has not been investigated in Egyptian population. Therefore, this study is planned to be a pilot study as a first study in Egypt.

Condition or Disease Intervention/Treatment Phase
  • Other: Questionnaire

Detailed Description

Cancer of the oral cavity is considered a global health burden. According to GLOBOCAN report of 2012, the incidence of oral cancer in Egypt was 1,687 per 10,000 per annum; while the mortality was 659 per 10,000 per annum. Statistically, the rates are expected to increase as to reach 2,658 per 10,000 incidence and 1,069 per 10,000 mortality by the year 2030.

Fortunately, 85% of head and neck cancers are visible. Therefore, the patient does not always need to visit a specialist for a special test to check for oral cancer. Instead, if the patients have basic knowledge about oral cancer, its signs and symptoms and its risk factors, they can detect the change themselves.

As a first step to reach this amazing goal, the level of awareness of the general population needs to be detected.

To the best of our knowledge, the awareness of oral cancer has not been assessed in the general population of Egypt before. As awareness of oral cancer is mandatory for dental practitioners, our study targets the general population other than those working in the dentistry field.

Study Design

Study Type:
Observational
Anticipated Enrollment :
5000 participants
Observational Model:
Ecologic or Community
Time Perspective:
Cross-Sectional
Official Title:
Oral Cancer Awareness Level in Egypt: a Pilot Cross-sectional Study
Anticipated Study Start Date :
Dec 1, 2022
Anticipated Primary Completion Date :
Jan 1, 2023
Anticipated Study Completion Date :
Jul 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Sample of the Egyptian population

Participants of Giza residents. Inclusion criteria: • Adult individuals (Age>18 years). Exclusion criteria: Dental students or dental practitioners; as awareness of the disease is an integral part of their profession. Oral cancer patients: Individuals who experience currently or previously having oral cancer. Individuals with mental or communication disabilities.

Other: Questionnaire
The questionnaire includes a section for socio-demographic data, a section to detect their general awareness of oral cancer as a disease, a section about their awareness of its signs and symptoms and lastly, a section about its risk factors and habits.

Outcome Measures

Primary Outcome Measures

  1. Level of awareness to oral cancer [6 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion criteria:
  • Adult individuals (Age>18 years).
Exclusion criteria:
  • Dental students or dental practitioners; as awareness of the disease is an integral part of their profession.

  • Oral cancer patients: Individuals who experience currently or previously having oral cancer.

  • Individuals with mental or communication disabilities.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Ayat Gamal-AbdelNaser
  • Ahram Canadian University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ayat Gamal-AbdelNaser, Principle investigator, Cairo University
ClinicalTrials.gov Identifier:
NCT05604105
Other Study ID Numbers:
  • ACU-Med1
First Posted:
Nov 3, 2022
Last Update Posted:
Nov 3, 2022
Last Verified:
Oct 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 3, 2022